RT Journal Article
SR Electronic
T1 Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.09.21266492
DO 10.1101/2021.12.09.21266492
A1 Rouhani, Sherin J
A1 Trujillo, Jonathan A
A1 Pyzer, Athalia R
A1 Yu, Jovian
A1 Fessler, Jessica
A1 Cabanov, Alexandra
A1 Higgs, Emily F
A1 Cron, Kyle R.
A1 Zha, Yuanyuan
A1 Lu, Yihao
A1 Bloodworth, Jeffrey C.
A1 Abasiyanik, Mustafa Fatih
A1 Okrah, Susan
A1 Flood, Blake A
A1 Hatogai, Ken
A1 Leung, Michael YK
A1 Pezeshk, Apameh
A1 Kozloff, Lara
A1 Reschke, Robin
A1 Strohbehn, Garth W.
A1 Chervin, Carolina Soto
A1 Kumar, Madan
A1 Schrantz, Stephen
A1 Madariaga, Maria Lucia
A1 Beavis, Kathleen G
A1 Yeo, Kiang-Teck J.
A1 Sweis, Randy F.
A1 Segal, Jeremy
A1 Tay, Savaş
A1 Izumchenko, Evgeny
A1 Mueller, Jeffrey
A1 Chen, Lin S
A1 Gajewski, Thomas F
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.12.09.21266492.abstract
AB The mechanisms explaining progression to severe COVID-19 remain poorly understood. It has been proposed that immune system dysregulation/over-stimulation may be implicated, but it is not clear how such processes would lead to respiratory failure. We performed comprehensive multiparameter immune monitoring in a tightly controlled cohort of 128 COVID-19 patients, and used the ratio of oxygen saturation to fraction of inspired oxygen (SpO2 / FiO2) as a physiologic measure of disease severity. Machine learning algorithms integrating 139 parameters identified IL-6 and CCL2 as two factors predictive of severe disease, consistent with the therapeutic benefit observed with anti-IL6-R antibody treatment. However, transcripts encoding these cytokines were not detected among circulating immune cells. Rather, in situ analysis of lung specimens using RNAscope and immunofluorescent staining revealed that elevated IL-6 and CCL2 were dominantly produced by infected lung type II pneumocytes. Severe disease was not associated with higher viral load, deficient antibody responses, or dysfunctional T cell responses. These results refine our understanding of severe COVID-19 pathophysiology, indicating that aberrant cytokine production by infected lung epithelial cells is a major driver of immunopathology. We propose that these factors cause local immune regulation towards the benefit of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe HIM and flow cytometry cores are supported by the University of Chicago Cancer Center Support Grant P30CA014599. and the Center for Research Informatics and RedCap are supported by UL1TR000430 from NCATS/NIH. SJR, JY and CSC are supported by the T32 CA009566. JAT is supported by 5K12CA139160–09 from NIH. RR was funded by the German Research Foundation (DFG RE 4468/1–1). MLM received funding from NIAID Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051. YL and LSC are supported by R01GM108711. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB the University of Chicago gave ethical approval for this work. The COVID-19 biobank study was approved by the University of Chicago Institutional Review Board (IRB 20-0520), and all procedures were performed in accordance with the ethical standards set forth in the 1964 Helsinki DeclarationI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors